0

HUMAN ANTIBODIES & HYBRIDOMAS 2020

Nascent Biotech founder Dr. Mark C. Glassy will once again be organizing and speaking at the Human Antibodies & Hybridomas conference, held 11-13 November 2020, The Richard Doll Building, [...]

0

Recent Publications from Nascent Biotech Founder Dr. Mark C. Glassy

Click each link to download individual publications in PDF format. Brain‐derived neurotrophic factor downregulation in gastric cancer Antibody drug conjugates: Progress, pitfalls, and promises [...]

0

Human Antibodies: Antibody drug conjugates: Progress, pitfalls, and promises

Nascent Biotech founder Dr. Mark C. Glassy has co-authored a new paper appearing in Human Antibodies entitled, “Antibody drug conjugates: Progress, pitfalls, and promises.” Please [...]

0

Prionogenicity of vimentin surmised from the sequelog of anti-idiotypic antibodies toward the paratope of malignant associated autologous anti-vimentin antibody, CLN-IgG (Pritumumab)

The British Journal of Cancer Research has just released a new paper co-authored by Nascent Biotech founder Dr. Mark C. Glassy entitled, “Prionogenicity of vimentin surmised from the [...]

0

The Economist: Closing In On Cancer

The Economist has published a fascinating overview of cancer research’s progress, including immunotherapy: The greatest excitement is reserved for immunotherapy, a new approach that has [...]

0

Nascent Biotech Announces Orphan Drug Designation for Pancreatic Cancer

Vero Beach, April 25th, 2016 – Nascent Biotech, Inc., (OTC.NBIO) is pleased to announce that it has been granted Orphan Drug Designation from the Office of Orphan Products Development of the FDA [...]

0

Nascent Biotech Achieves Two Key Milestones in Development of its Novel Brain Cancer Treatment

San Diego, CA August 13, 2015 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO). Since March of 2014 Nascent has raised $2.1 million which has been used to advance the [...]

0

Nascent Biotech, Inc. Announces 2 Additions to Scientific Advisory Board

San Diego, CA June 17, 2014 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO), announces announced that it has added two internationally renowned cancer experts to its [...]

0

2015 Human Antibodies & Hybridomas Conference

Nascent Biotech will be a key sponsor of the 2015 edition of the Human Antibodies & Hybridomas Conference, held October 28-30, 2015, at the University of Lausanne/CHUV, in Lausanne, [...]

0

Nascent team members author “Oligoclonal and Polyclonal Antibody Preparations” paper

Nascent founder and chief executive officer Dr. Mark C. Glassy and chief science officer Dr. Rishab K. Gupta authored a new paper published in the Handbook of Therapeutic Antibodies, Second [...]

page 1 of 2